Overview

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Status:
Completed
Trial end date:
2000-10-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Cyclophosphamide
Cyclosporine
Cyclosporins
Methotrexate
Criteria
DISEASE CHARACTERISTICS: Any of the following hematologic malignancies: Acute myelogenous
leukemia in second or greater remission or relapse High risk acute lymphoblastic leukemia
First complete remission with high risk cytogenetics [e.g., t(9;22), t(8;14), or t(4;11)]
or slow early response OR Any second or greater remission OR Relapse or induction failure
Relapsed non-Hodgkin's lymphoma (NHL) with chemotherapy sensitive disease Multiple myeloma
with chemotherapy sensitive disease Chronic lymphocytic leukemia with chemotherapy
sensitive disease Myelodysplastic syndrome Chronic myelogenous leukemia (CML) in
accelerated phase, blast phase, or remission after blast phase Juvenile CML Patients must
have haploidentical donors and meet the following criteria: Lack an HLA A, B, and DR
matched related donor Lack an HLA A, B, DRB1 matched or single allele mismatched unrelated
donor or for whom the following apply: High likelihood of rapid disease progression while
an unrelated donor search is in progress AND Review of the patient HLA typing, gene
frequency, results of the preliminary search and the donor pool suggest that a donor will
not be found within a suitable time frame Lack an HLA A, B, DRB1 matched cord blood unit or
lack a cord blood unit that has an adequate cell dose and is mismatched for 1-2 HLA A, B,
DRB1 Do not have an indication for autologous transplant, including patients with NHL or
multiple myeloma who are not eligible for autologous transplant Negative antidonor antibody
crossmatch

PATIENT CHARACTERISTICS: Age: Under 51 Performance status: Not specified Life expectancy:
No patients with life expectancy severely limited by diseases other than malignancy
Hematopoietic: See Disease Characteristics Hepatic: AST no greater than 2 times normal
Renal: Creatinine no greater than 2 times normal OR Creatinine clearance at least 50% for
age, weight, and height Cardiovascular: No cardiac insufficiency requiring treatment No
symptomatic coronary artery disease Pulmonary: No severe hypoxemia pO2 less than 70 mm Hg
with decreased DLCO less than 70% predicted OR No mild hypoxemia pO2 less than 80 mm Hg
with severely decreased DLCO less than 60% predicted Other: HIV negative Not pregnant or
nursing Fertile patients must use effective contraception during and for one year after
study No leukoencephalopathy

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
Endocrine therapy: Not specified Radiotherapy: No more than 3,000 cGy prior radiotherapy to
brain No more than 1,500 cGy prior radiotherapy to chest or abdomen Surgery: Not specified